Ken Griffin Verona Pharma PLC Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 140,100 shares of VRNA stock, worth $4.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,100

Previous 17,700 691.53%

Holding current value

$4.64 Million

Previous $284,000 613.03%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.48 - $17.02 $454,573 - $673,940	-39,597 Reduced 27.84%	102,615 $1.48 Million
Q1 2024 May 15, 2024	BUY	$15.3 - $20.24 $1.74 Million - $2.31 Million	114,022 Added 404.48%	142,212 $2.29 Million
Q4 2023 Feb 14, 2024	SELL	$11.94 - $20.47 $1.77 Million - $3.04 Million	-148,293 Reduced 84.03%	28,190 $560,000
Q3 2023 Nov 14, 2023	SELL	$16.3 - $22.09 $1.78 Million - $2.42 Million	-109,383 Reduced 38.26%	176,483 $2.88 Million
Q2 2023 Aug 14, 2023	BUY	$19.41 - $23.43 $341,965 - $412,789	17,618 Added 6.57%	285,866 $6.04 Million
Q1 2023 May 15, 2023	BUY	$18.06 - $25.27 $4.84 Million - $6.78 Million	268,248 New	268,248 $5.39 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $2.83 Million - $9.3 Million	684,511 Added 6368.14%	695,260 $7.11 Million
Q2 2022 Aug 15, 2022	SELL	$3.55 - $5.06 $4,047 - $5,768	-1,140 Reduced 9.59%	10,749 $45,000
Q4 2021 Feb 14, 2022	SELL	$3.91 - $7.08 $42,935 - $77,745	-10,981 Reduced 48.01%	11,889 $79,000
Q3 2021 Nov 15, 2021	BUY	$5.29 - $6.35 $120,982 - $145,224	22,870 New	22,870 $125,000
Q2 2019 Aug 14, 2019	SELL	$5.1 - $6.91 $55,202 - $74,793	-10,824 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.52 - $10.0 $59,748 - $108,240	10,824 New	10,824 $0

Others Institutions Holding VRNA

# of Institutions

145

Shares Held

66.8M

Call Options Held

495K

Put Options Held

486K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.02B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account